Lung Cancer News

Using whole-body magnetic resonance imaging for staging in non-small-cell lung cancer reduced staging time, cut costs and had similar diagnostic accuracy when compared with current standard cancer staging pathways, according to a study published in The Lancet Respiratory Medicine.

PHILADELPHIA — The role e-cigarettes play on tobacco dependence, the morbidity and potentially mortality from tobacco is “unclear,” a speaker said at the American College of Physicians Internal Medicine Meeting.

PHILADELPHIA — An approach to smoking cessation that treats nicotine addiction as a medical condition that must be controlled is usually more effective than other smoking cessation methods, a speaker at the American College of Physicians Internal Medicine meeting said.

The FDA expanded the approval of pembrolizumab to include the first-line treatment of patients with stage III non-small cell lung cancer who are not able to undergo surgical resection or definitive chemoradiation, as well as those with metastatic disease.

FORT WORTH, Texas — Patients with non-small cell lung cancer exposed to immunotherapy as second-line treatment achieved clinically meaningful PFS after receiving chemotherapy in the third-line setting, according to study results presented at HOPA Ahead 2019.

FORT WORTH, Texas — An evaluation of physician prescribing practices showed utilization of corticosteroids for management of immune-mediated adverse events among patients with cancer who received immune checkpoint inhibitors often was not based on national guidelines, according to study results presented at HOPA Ahead 2019.

NEW YORK — Benjamin P. Levy, MD, associate professor at Johns Hopkins School of Medicine and clinical director of Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, spoke to attendees at HemOnc Today New York about salvage treatment options for patients with non-small cell lung cancer.

A phase 2 trial designed to evaluate the safety and efficacy of lurbinectedin for patients with relapsed small cell lung cancer met its primary endpoint of overall response rate, according to the agent’s manufacturer.

Two faculty members at HemOnc Today New York debated whether immunotherapy alone or in combination with chemotherapy is the ideal treatment approach for lung cancer.

Molecular therapy for the treatment of lung cancer has not evolved enough to adequately extend survival of patients, according to a presenter at HemOnc Today New York.